Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. on September 25, 2008. The report discloses a corporate governance event regarding the appointment of a senior officer. Note: The request metadata references "Sonoma Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Oculus Innovative Sciences, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the promotion of Mr. Bruce Thornton from Vice President International Operations and Sales to Executive Vice President, effective October 1, 2008. His responsibilities will expand to include U.S. operations in addition to his existing international duties.
Management Commentary and Compensation
- Compensation Adjustment: Mr. Thornton's annual compensation will increase from $225,000 to $250,000 for the remainder of fiscal year 2009.
- Background: Mr. Thornton, age 44, has served the company since June 2005 and previously held roles at Jomed and Volcano Therapeutics.
- Risks and Contingencies: The filing text does not provide a clear value or discussion regarding new risks, contingencies, or unusual items beyond the executive appointment.
Investor Verification Checklist
- Verify the effective date of the Executive Vice President appointment (October 1, 2008).
- Confirm the specific scope of expanded responsibilities for U.S. operations.
- Review the total compensation package details to ensure the $250,000 figure reflects the full annualized rate for the remainder of fiscal 2009.
- Check subsequent filings for any impact of this leadership change on operational strategy.